Ismail, Anis
Hayek, Salim S.
Funding for this research was provided by:
National Institutes of Health (NHLBI R01HL153384)
Gilead Sciences Research Scholar Program
Article History
Accepted: 1 November 2023
First Online: 10 November 2023
Compliance with Ethical Standards
:
: Anis Ismail has no conflicts of interest. Salim S. Hayek reports personal fees from Walden Biosciences and Siemens, outside the submitted work. In addition, Dr. Hayek has patents pending on “Use of soluble urokinase plasminogen activator receptor levels in the management of patients with cardiovascular disease” and “Methods to target the soluble urokinase plasminogen activator receptor pathway for the prevention and treatment of atherosclerosis.”
: This article does not contain any studies with human or animal subjects performed by any of the authors.